Prakash Ambady1, Rongwei Fu2, Laszlo Szidonya1, David M Peereboom3, Nancy D Doolittle1, Edward A Neuwelt4,5,6. 1. Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L603, Portland, OR, 97239, USA. 2. School of Public Health, Department of Clinical Epidemiology and Medical Informatics, Oregon Health & Science University, Portland, OR, USA. 3. Burkhardt Brain Tumor Center, Cleveland Clinic, Cleveland, OH, USA. 4. Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L603, Portland, OR, 97239, USA. neuwelte@ohsu.edu. 5. Department of Neurosurgery, Oregon Health & Science University, Portland, OR, USA. neuwelte@ohsu.edu. 6. Portland Veterans Affairs Medical Center, Portland, OR, USA. neuwelte@ohsu.edu.
Abstract
PURPOSE: The role of maintenance immunotherapy with anti-CD20 monoclonal antibody rituximab in primary central nervous system lymphoma (PCNSL) is unclear. We retrospectively reviewed the medical records of all immunocompetent adults with newly diagnosed PCNSL treated at our institution between1996 and 2017. METHODS: We identified 66 patients who attained complete response (CR) after completion of first-line regimen; 20 received maintenance therapy (maintenance therapy group) and 46 were observed with serial MRI scans without maintenance therapy (no-maintenance therapy group). RESULTS: Compared to the surveillance group, there was a significant increase in duration of survival (HR 0.27, 95% CI 0.08-0.98, P = 0.046) in the maintenance therapy group while the reduction in the risk of progression was not significant (HR: 0.61, 95% CI 0.26-1.43, P = 0.259). CONCLUSION: We are evaluating the effectiveness of maintenance immunotherapy in PCNSL in a prospective multicenter randomized clinical trial.
PURPOSE: The role of maintenance immunotherapy with anti-CD20 monoclonal antibody rituximab in primary central nervous system lymphoma (PCNSL) is unclear. We retrospectively reviewed the medical records of all immunocompetent adults with newly diagnosed PCNSL treated at our institution between1996 and 2017. METHODS: We identified 66 patients who attained complete response (CR) after completion of first-line regimen; 20 received maintenance therapy (maintenance therapy group) and 46 were observed with serial MRI scans without maintenance therapy (no-maintenance therapy group). RESULTS: Compared to the surveillance group, there was a significant increase in duration of survival (HR 0.27, 95% CI 0.08-0.98, P = 0.046) in the maintenance therapy group while the reduction in the risk of progression was not significant (HR: 0.61, 95% CI 0.26-1.43, P = 0.259). CONCLUSION: We are evaluating the effectiveness of maintenance immunotherapy in PCNSL in a prospective multicenter randomized clinical trial.
Authors: Lauren E Abrey; Tracy T Batchelor; Andrés J M Ferreri; Mary Gospodarowicz; Elisa J Pulczynski; Emanuele Zucca; Justine R Smith; Agnieszka Korfel; Carole Soussain; Lisa M DeAngelis; Edward A Neuwelt; Brian Patrick O'Neill; Eckhard Thiel; Tamara Shenkier; Fransesc Graus; Martin van den Bent; John F Seymour; Philip Poortmans; James O Armitage; Franco Cavalli Journal: J Clin Oncol Date: 2005-06-13 Impact factor: 44.544
Authors: N D Doolittle; M E Miner; W A Hall; T Siegal; E Jerome; E Osztie; L D McAllister; J S Bubalo; D F Kraemer; D Fortin; R Nixon; L L Muldoon; E A Neuwelt Journal: Cancer Date: 2000-02-01 Impact factor: 6.860
Authors: Matthias Holdhoff; Prakash Ambady; Ahmed Abdelaziz; Guneet Sarai; David Bonekamp; Jaishri Blakeley; Stuart A Grossman; Xiaobu Ye Journal: Neurology Date: 2014-06-13 Impact factor: 9.910
Authors: James L Rubenstein; Jane Fridlyand; Lauren Abrey; Arthur Shen; Jon Karch; Endi Wang; Samar Issa; Lloyd Damon; Michael Prados; Michael McDermott; Joan O'Brien; Chris Haqq; Marc Shuman Journal: J Clin Oncol Date: 2007-02-20 Impact factor: 44.544
Authors: Lilyana Angelov; Nancy D Doolittle; Dale F Kraemer; Tali Siegal; Gene H Barnett; David M Peereboom; Glen Stevens; John McGregor; Kristoph Jahnke; Cynthia A Lacy; Nancy A Hedrick; Edna Shalom; Sandra Ference; Susan Bell; Lisa Sorenson; Rose Marie Tyson; Marianne Haluska; Edward A Neuwelt Journal: J Clin Oncol Date: 2009-05-18 Impact factor: 44.544
Authors: E A Neuwelt; D L Goldman; S A Dahlborg; J Crossen; F Ramsey; S Roman-Goldstein; R Braziel; B Dana Journal: J Clin Oncol Date: 1991-09 Impact factor: 44.544
Authors: Howard Hochster; Edie Weller; Randy D Gascoyne; Thomas M Habermann; Leo I Gordon; Theresa Ryan; Lijun Zhang; Natalia Colocci; Stanley Frankel; Sandra J Horning Journal: J Clin Oncol Date: 2009-03-02 Impact factor: 44.544
Authors: Mallika P Patel; John P Kirkpatrick; Margaret O Johnson; Patrick Healy; James E Herndon; Eric S Lipp; Elizabeth S Miller; Annick Desjardins; Dina Randazzo; Henry S Friedman; David M Ashley; Katherine B Peters Journal: J Neurooncol Date: 2020-03-05 Impact factor: 4.130